Informal Caregiver Time and Associated Cost in Patients with Alzheimer's Disease in the United States (US): **EE491 A Systematic Literature Review** Sumeet Attri¹, Ritesh Dubey¹, Gunjan Bisht¹, Shubhram Pandey¹, Barinder Singh² Evidence[®] ¹Pharmacoevidence, SAS Nagar, Mohali, PB, India, ²Pharmacoevidence, London, UK

Conclusion

Background

- Alzheimer's Disease (AD), a leading cause of dementia, is a progressive disease of the brain that results in significant social and economic costs to patients, caregivers, and society
- Caregivers may experience burden and stress under certain circumstances, but there are different thresholds for triggering caregiver burden
- Zarit and colleagues provided a useful definition: "The extent to which caregivers perceive that caregiving has had an adverse effect on their emotional, social, financial, physical, and spiritual functioning"

Objective-

The systematic literature review (SLR) aimed to identify studies conducted in the US evaluating the informal caregiver time and associated indirect costs (IC) in patients with AD

Methodology

- The review followed the standard methodology for conducting reviews as per National Institute for Health and Care Excellence (NICE), Cochrane Handbook, and PRISMA guidelines
- Embase[®] and MEDLINE[®] were searched for English language studies conducted in the US and published between Jan 2011 and Jan 2023, providing the informal caregiver time and associated IC
- The SLR followed two review and quality control process as recommended by various HTAs
- Figure 1 presents the eligibility criteria for selection of evidence



• Informal care provided by family and friends of elderly AD patients is unpaid and usually underestimated. The current research highlights the impact of informal care and its associated cost on the total societal burden of AD, which is immense and subsequently increases with AD severity







Sponsorship



This research is conducted solely by the authors without any collaboration from other institutes or pharmaceutical/biotech companies

Severe severity of dementia (MMSE <10)

